316 related articles for article (PubMed ID: 31310636)
1. Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis.
Jülicher P; Chulanov VP; Pimenov NN; Chirkova E; Yankina A; Galli C
PLoS One; 2019; 14(7):e0219687. PubMed ID: 31310636
[TBL] [Abstract][Full Text] [Related]
2. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.
Jülicher P; Galli C
J Med Econ; 2018 Jan; 21(1):1-10. PubMed ID: 28881157
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users.
Cipriano LE; Zaric GS; Holodniy M; Bendavid E; Owens DK; Brandeau ML
PLoS One; 2012; 7(9):e45176. PubMed ID: 23028828
[TBL] [Abstract][Full Text] [Related]
5. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
[TBL] [Abstract][Full Text] [Related]
6. Routine screening for hepatitis C viral infection in patients undergoing elective cranial neurosurgery.
Nussbaum ES; Kallmes K; Lowary J; Nussbaum LA
J Neurosurg; 2018 Sep; 131(3):941-948. PubMed ID: 30215562
[TBL] [Abstract][Full Text] [Related]
7. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
9. Community screening for hepatitis C virus infection in a low-prevalence population.
Kyuregyan KK; Malinnikova EY; Soboleva NV; Isaeva OV; Karlsen AA; Kichatova VS; Potemkin IA; Schibrik EV; Gadjieva OA; Bashiryan BA; Lebedeva NN; Serkov IL; Yankina A; Galli C; Mikhailov MI
BMC Public Health; 2019 Aug; 19(1):1038. PubMed ID: 31375104
[TBL] [Abstract][Full Text] [Related]
10. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
[TBL] [Abstract][Full Text] [Related]
11. Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
Buti M; Domínguez-Hernández R; Casado MÁ; Sabater E; Esteban R
PLoS One; 2018; 13(11):e0208036. PubMed ID: 30485377
[TBL] [Abstract][Full Text] [Related]
12. Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.
Opstaele L; Bielen R; Bourgeois S; Moreno C; Nevens F; Robaeys G; Robaeys G; Van Vlierberghe H
Acta Gastroenterol Belg; 2019; 82(3):379-387. PubMed ID: 31566325
[TBL] [Abstract][Full Text] [Related]
13. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
Linas BP; Wong AY; Schackman BR; Kim AY; Freedberg KA
Clin Infect Dis; 2012 Jul; 55(2):279-90. PubMed ID: 22491339
[TBL] [Abstract][Full Text] [Related]
14. Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison.
Babigumira JB; Karichu JK; Clark S; Cheng MM; Garrison LP; Maniecki MB; Hamid SS
BMJ Open; 2023 May; 13(5):e066770. PubMed ID: 37142306
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
16. Economic model of a birth cohort screening program for hepatitis C virus.
McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups.
Nakamura J; Terajima K; Aoyagi Y; Akazawa K
Tohoku J Exp Med; 2008 May; 215(1):33-42. PubMed ID: 18509233
[TBL] [Abstract][Full Text] [Related]
18. The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands.
Al Khayat MNMT; Eijsink JFH; Postma MJ; Wilschut JC; van Hulst M
Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32825680
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan.
Wang JH; Chen CH; Chang CM; Feng WC; Lee CY; Lu SN
J Formos Med Assoc; 2020 Jan; 119(1 Pt 3):504-508. PubMed ID: 31350109
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.
Kim HL; Kim KA; Choi GH; Jang ES; Ki M; Choi HY; Jeong SH
Clin Mol Hepatol; 2022 Jan; 28(1):91-104. PubMed ID: 34736311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
